Oxford Drug Design

N-Leucinyl Benzenesulfonamides as LeuRS Inhibitors

ODD scientists and collaborators have published a research paper describing the discovery of a new class of aminoacyl-tRNA synthetase inhibitors, N-Leucinyl benzenesulfonamides. The binding of inhibitors to the enzyme was measured by using isothermal titration calorimetry. This provided information on enthalpy and entropy contributions to binding, which, together with docking studies, were used for structure–activity relationship analysis. Enzymatic assays revealed that N-leucinyl benzenesulfonamides display remarkable selectivity for E. coli leucyl-tRNA synthetase compared to S. aureus and human orthologues. The simplest analogue of the series, N-leucinyl benzenesulfonamide, showed the highest affinity against E. coli leucyl-tRNA synthetase and also exhibited antibacterial activity against Gram-negative pathogens, which renders it as a promising template for antibacterial drug discovery.

Read the full article published in ACS Medicinal Chemistry Letters.


Oxford Drug Design Ltd
Oxford Centre for Innovation
New Road
Oxford OX1 1BY, UK

contactus@oxforddrugdesign.com
+44 (0)1865 261468

Quick Links
© Oxford Drug Design. All Rights Reserved 2023. Legal Information. Site Design by Koma.live